Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  ResMed Inc.    RMD

Delayed Quote. Delayed  - 05/02 10:02:03 pm
56.13 USD   +0.59%
04/28 RESMED : Sellers Covered 2.14% of Their Shorts
04/27 Ironwood Pharmaceuticals & ResMed, are Worth Watching Stocks
04/26 RESMED : misses 3Q profit forecasts
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Analysis summary4-Traders Strategies 

ResMed Inc. : Trading opportunity

share with twitter share with LinkedIn share with facebook
share via e-mail
02/15/2013 | 11:07am
Opinion : Bullish above USD 42.8
Target price : USD 48.4
Stop loss: USD 40.6
NYSE
Advanced Medical Equipment & Technology

ResMed could regain its upward trend after having run out of steam.

According to Surperformance ratings, the group has strong fundamentals,as shown by the business predictability. In addition, analysts have recently revised upward their earnings estimates and now expect a profit of USD 2.19 per share for the current year.

ResMed is in an uptrend in the medium and long term, but the last bearish movement returns close to a major support level (USD 42.8), level corresponding to the 20-week moving average. This threshold, if preserved, will enable to enjoy the bullish movement towards the USD 48.4 resistance.

It seems opportune to take a long position around the USD 42.8 support area with in line of sight the USD 48.4 resistance. A stop loss must be placed under the USD 42.8 support.

ResMed Inc. : ResMed Inc. : Trading opportunity

© Zonebourse.com 2013



share with twitter share with LinkedIn share with facebook
share via e-mail

Disclaimer: 4-traders.com is a website published by SURPERFORMANCE SAS. Surperformance or 4-traders.com is not a registered broker-dealer nor a registered investment adviser. You understand that this web site and its content is furnished for your personal, noncommercial, informational purposes only, and that no mention of a particular security in this website constitutes a recommendation to buy, sell, or hold any other security, nor that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person. Surperformance and 4-traders.com services will not advise you personally concerning the nature, potential, value or suitability of any particular security, portfolio of securities, transaction, investment strategy or other matter. Information regarding trading and investment as provided by Surperformance professional is not tailored to the investment needs of any specific person. You acknowledge that you are responsible for your own financial decisions and should seek a registered financial agent depending on your own risk tolerance to advise you on your personal trading activities.

Advertisement
Financial Ratios

Size 2016e 2017e
Capitalization 7 835 M$ -
Entreprise Value (EV) 8 172 M$ 7 957 M$
Valuation 2016e 2017e
P/E ratio (Price / EPS) 21,9x 19,2x
Capitalization / Revenue 4,28x 3,79x
EV / Revenue 4,47x 3,84x
EV / EBITDA 15,2x 12,9x
Yield (DPS / Price) 2,27% 2,47%
Price to book (Price / BVPS) 4,54x 4,04x
Profitability 2016e 2017e
Operating Margin (EBIT / Sales) 24,5% 24,9%
operating Leverage (Delta EBIT / Delta Sales) 0,50x 1,14x
Net Margin (Net Profit / Revenue) 19,8% 19,8%
ROA (Net Profit / Asset) 16,3% 15,0%
ROE (Net Profit / Equities) 22,1% 22,9%
Rate of Dividend 49,9% 47,4%
Balance Sheet Analysis 2016e 2017e
CAPEX / Sales   3,91% 3,48%
Cash Flow / Sales 22,6% 21,1%
Capital Intensity (Assets / Sales) 1,22x 1,32x
Financial Leverage (Net Debt / EBITDA) 0,63x 0,20x
Income Statement Evolution
More Financials
EPS Revisions